Novavax Global Commercial Operations and COVID-19 Vaccine Update

Study met co-primary endpoints supporting strain change BA.1 Neutralizing antibodies BA.1 Geometric Mean Titer (GMT) (95% CI) BA.1 vaccine Prototype vaccine 88.6 (73.5, 106.7) 135.6 (111.6, 164.9) Geometric Mean Ratio (GMR) (95% CI) 1.6 (1.31, 2.03) >4-fold Seroconversion Rate 73.4 (SCR) (64.1, 81.4) 51.4 (41.6, 61.1) (95% CI) Difference in SCR (95% CI) 22.0 (9.2, 34.2) Superiority of BA.1 vaccine vs prototype for GMTs demonstrated as lower-bound of 95% CI for GMT ratio is > 1 Non-inferiority of BA.1 vaccine vs prototype for SCRS demonstrated as lower-bound of 95% CI for difference of SRR is > -5% novavax © 2023 NOVAVAX. All rights reserved. NK 54 54

View entire presentation